TASE

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease

Friday, October 15, 2021 - 1:37pm

Of the 78 patients that enrolled in the BALANCE Study, 72 have completed the trial's twoyear treatment period.

Key Points: 
  • Of the 78 patients that enrolled in the BALANCE Study, 72 have completed the trial's twoyear treatment period.
  • "We are grateful to the patients and investigators whose participation and dedication have played a critical role in advancing this phase III program," said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.
  • "The final dosing of the last patient in the BALANCE Study is another important milestone in our ongoing efforts to improve support for individuals living with Fabry disease and their families."
  • The BALANCE study is a 24month, randomized, double blind, active control study of PRX102 in Fabry patients with impaired renal function.

ICL Expands Potassium Nitrate Supply Arrangement with Haldor Topsoe

Thursday, October 14, 2021 - 9:10pm

ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced its intention to expand its current commercial relationship with Haldor Topsoe and is looking forward to entering into a long-term supply arrangement for potassium nitrate.

Key Points: 
  • ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced its intention to expand its current commercial relationship with Haldor Topsoe and is looking forward to entering into a long-term supply arrangement for potassium nitrate.
  • ICL expects to expand its NOP sourcing from Haldor Topsoe and begin marketing product in the first quarter of 2022, as it further integrates Topsoe material into its global supply offerings.
  • Haldor Topsoe has been a trusted supplier for the past several years, and this arrangement expands our existing relationship and allows both of us to advance our sustainability efforts, said Heinrich Berger, vice president of global raw materials procurement for ICL.
  • Haldor Topsoe is a global leader in supply of catalysts, technology, and services to the chemical and refining industries.

DGAP-News: Foresight Announces QuadSight(R) Sale to a North American Robotic Systems Developer

Thursday, October 14, 2021 - 2:29pm

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that it has received an order for a prototype of its QuadSight(R) four-camera vision system from a leading North American robotic systems developer.

Key Points: 
  • Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that it has received an order for a prototype of its QuadSight(R) four-camera vision system from a leading North American robotic systems developer.
  • For example, Foresight is using forward-looking statements in this press release when it discusses the evaluation of Foresight's technology by the North American robotic systems developer.
  • Through the Company's wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both 'in-line-of-sight' vision systems and 'beyond-line-of-sight' accident-prevention solutions.
  • For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com , follow @ForesightAuto1 on Twitter, or join Foresight Automotive on LinkedIn.

Medigus: Gix Completed Acquisition of Leading Media-Tech Company Cortex Group for Approximately $11 Million

Thursday, October 14, 2021 - 12:57pm

Cortex was established in 2017 and has since been operating with remarkable success in the field of online advertising.

Key Points: 
  • Cortex was established in 2017 and has since been operating with remarkable success in the field of online advertising.
  • Cortex is an innovative media-tech company that has developed capabilities that enable the conversion of original content into a profit center by acquiring user traffic.
  • Cortexs business model is based on purchasing advertising space from publishers such as YAHOO, Outbrain, Verizon-Oath, Google and more.
  • During the third quarter of 2021, Cortex continued to present an impressive growth, with revenues amounting to approximately $12.5 million (NIS 40 million), an increase of 92% compared with revenues in the corresponding quarter last year.

Frost & Sullivan analysts' coverage of Aura Smart Air

Thursday, October 14, 2021 - 12:00pm

Aura Smart Air Ltd. (TASE: AUSA) was established in 2018 to provide an international standard and technology platfrom to manage air quality in enclosed spaces.

Key Points: 
  • Aura Smart Air Ltd. (TASE: AUSA) was established in 2018 to provide an international standard and technology platfrom to manage air quality in enclosed spaces.
  • Strategy Aura Smart Air offers hardware and software to its customers, with its business split into 3 main areas: (i) HW & SW product sales; (ii) services, including parts and updates; and (iii) data.
  • Aura Smart Air is differentiated from its competition due to its lower cost, ease of instillation and maintenance, and engineering structure.
  • In our view, Aura Smart Air is at the forefront of the rapidly growing Indoor Air Quality (IAQ) market.

Nova to Announce Third Quarter 2021 Financial Results on November 4, 2021

Thursday, October 14, 2021 - 12:00pm

A replay of the conference call will be available fromNovember 4, 2021, to November 11, 2021.

Key Points: 
  • A replay of the conference call will be available fromNovember 4, 2021, to November 11, 2021.
  • Nova delivers continuous innovation by providing state-of-the-art high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle.
  • Nova acts as a partner to semiconductor manufacturers from its offices around the world.
  • Nova Ltd. does not assume any obligation to update the forward-looking information contained in this press release.

OCP Group and ICL Join Forces to Support Sustainability Programs at UM6P and BGU

Wednesday, October 13, 2021 - 9:10pm

OCP Group and ICL Group signed today a memorandum of understanding to offer scholarships to promote research and academic excellence through the funding of sustainability programs at Mohammed VI Polytechnic University (UM6P) and Ben-Gurion University of the Negev (BGU).

Key Points: 
  • OCP Group and ICL Group signed today a memorandum of understanding to offer scholarships to promote research and academic excellence through the funding of sustainability programs at Mohammed VI Polytechnic University (UM6P) and Ben-Gurion University of the Negev (BGU).
  • For the implementation of these activities, OCP Group will provide initial funding of $300,000 to UM6P, and ICL Group will provide a similar amount to BGU, for a total of $US 600,000.
  • Daniel Chamovitz, President of Ben-Gurion University of the Negev said, BGU and UM6P have much in common.
  • ICL shares are dually listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL).

InterCure to Present in Benzinga Cannabis Capital Conference

Wednesday, October 13, 2021 - 5:15pm

(NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the Company) today announced that Alexander Rabinovitch, CEO of InterCure, will present at the Benzinga Cannabis Capital Conference on Thursday, October 14, 2021 at 1:50pm ET.

Key Points: 
  • (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the Company) today announced that Alexander Rabinovitch, CEO of InterCure, will present at the Benzinga Cannabis Capital Conference on Thursday, October 14, 2021 at 1:50pm ET.
  • To register for the conference, please visit the conference website: https://www.benzinga.com/events/cannabis/october-2021/#who-attends
    If you are interested in scheduling a one-on-one meeting with InterCures management team, please contact InterCure@kcsa.com .
  • InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America.
  • Canndoc, a wholly owned subsidiary of InterCure, is Israels largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Tower Semiconductor to Hold its 2021 Annual Technical Global Symposium Online Event

Wednesday, October 13, 2021 - 12:00pm

Presenting technology solutions and development roadmaps addressing the rising demands of the communication, automotive, medical, AI, advanced displays and industrial markets

Key Points: 
  • Presenting technology solutions and development roadmaps addressing the rising demands of the communication, automotive, medical, AI, advanced displays and industrial markets
    MIGDAL HAEMEK, Israel, October 13, 2021 Tower Semiconductor (NASDAQ/TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, today announced its online 2021 annual Technical Global Symposium.
  • In addition, Companys global manufacturing capabilities, solutions, and capacity growth programs will be presented.
  • Tower does not intend to update, and expressly disclaim any obligation to update, the information contained in this release.
  • Tower Semiconductor Investor Relations Contact: Noit Levy | +972-4-604-7066 | noitle @towersemi.com

BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

Wednesday, October 13, 2021 - 1:30pm

TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Global Health Economics and Outcomes Research (HEOR) team of IQVIA, and was a pre-planned study conducted in parallel with the GENESIS Phase 3 trial. These results, together with the highly significant and clinically meaningful data from the GENESIS trial, strongly support the potential use of Motixafortide, on top of G-CSF, as the standard of care in SCM for ASCT.

Key Points: 
  • These cost savings should leave substantial room in the future to optimize our pricing strategy for Motixafortide at product launch and thereafter, if approved.
  • "It is also important to note that fewer administrations and apheresis sessions confer meaningful safety and time benefits to patients.
  • "We believe the data from the GENESIS study, together with the results from this pharmacoeconomic study, set Motixafortide apart from all other mobilization agents either currently available or in development.
  • Motixafortide plus G-CSF was associated with a statistically significant HRU decrease during the autologous stem cell transplantation process compared to standard-of-care G-CSF alone.